| scholarly article | Q13442814 |
| P50 | author | Ralph Steinman | Q105494 |
| Rod Dunbar | Q62238911 | ||
| P2093 | author name string | D F Nixon | |
| S M Donahoe | |||
| M Sapp | |||
| N Bhardwaj | |||
| V Cerundolo | |||
| M V Dhodapkar | |||
| H Desai | |||
| J Krasovsky | |||
| C Fossella | |||
| P2860 | cites work | Dendritic cells and the control of immunity | Q27860918 |
| Phenotypic analysis of antigen-specific T lymphocytes | Q28290058 | ||
| Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells | Q34229490 | ||
| Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma | Q36119828 | ||
| The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation | Q68617051 | ||
| Induction of antitumor immunity using bone marrow-generated dendritic cells | Q71020321 | ||
| Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen | Q71931319 | ||
| A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells | Q73821429 | ||
| Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells | Q74310288 | ||
| Cancer vaccines | Q74539555 | ||
| Fully mobilizing host defense: building better vaccines | Q77608031 | ||
| Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses | Q36365628 | ||
| Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity | Q36366051 | ||
| Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines | Q36366108 | ||
| CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells | Q37698653 | ||
| Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 | ||
| Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma | Q41044788 | ||
| Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines | Q41415648 | ||
| Antiviral immunity | Q41504874 | ||
| Dendritic cells as adjuvants for immune-mediated resistance to tumors | Q41649620 | ||
| Rapid effector function in CD8+ memory T cells | Q41847748 | ||
| Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. | Q44572777 | ||
| A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals | Q45749114 | ||
| Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group | Q45756090 | ||
| A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. | Q46023106 | ||
| Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells | Q46578425 | ||
| Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine | Q47837811 | ||
| Antigen presentation and related immunological aspects of HIV-1 vaccines. | Q47952918 | ||
| A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell | Q47982760 | ||
| Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. | Q52039523 | ||
| Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. | Q54451826 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 173-180 | |
| P577 | publication date | 1999-07-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells | |
| P478 | volume | 104 |
| Q44245789 | A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy |
| Q52133911 | A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. |
| Q52017917 | A dynamical perspective of CTL cross-priming and regulation: implications for cancer immunology. |
| Q60734679 | A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use |
| Q52822549 | A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients. |
| Q33645564 | A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy |
| Q36370927 | A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma |
| Q35176366 | A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy |
| Q39853571 | Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation |
| Q34002678 | Active immunization of humans with dendritic cells |
| Q33846007 | Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy |
| Q36974722 | Advances in dendritic-cell-based therapeutic vaccines for cervical cancer |
| Q34088814 | Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity |
| Q44024646 | Ambivalent effects of dendritic cells displaying prostaglandin E2-induced indoleamine 2,3-dioxygenase |
| Q40375320 | An appreciation of Ralph Marvin Steinman (1943–2011). |
| Q35747229 | An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens |
| Q40389502 | An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats |
| Q44473359 | Antigen loading of dendritic cells with whole tumor cell preparations |
| Q36369028 | Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells |
| Q36376481 | Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells |
| Q39984018 | Assessment of migration of HIV-1-loaded dendritic cells labeled with 111In-oxine used as a therapeutic vaccine in HIV-1-infected patients |
| Q53538542 | Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies. |
| Q33897693 | Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance |
| Q34452007 | Biological and clinical developments in melanoma vaccines |
| Q43805226 | Bipartite regulation of different components of the MHC class I antigen-processing machinery during dendritic cell maturation |
| Q36392561 | Bone marrow dendritic cell-mediated regulation of TLR and B cell receptor signaling in B cells |
| Q33709425 | CD40-activated B cells induce anti-tumor immunity in vivo |
| Q34476278 | CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells |
| Q35794652 | Cancer vaccine development: protein transfer of membrane-anchored cytokines and immunostimulatory molecules |
| Q35137164 | Cellular immunotherapy after autologous hematopoietic stem cell transplantation: experimental strategies and clinical experiences |
| Q35856643 | Characterization of canine monocyte-derived dendritic cells with phenotypic and functional differentiation |
| Q36742276 | Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells |
| Q34189203 | Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. |
| Q64129433 | Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety |
| Q44889298 | Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage |
| Q43259670 | Comparison of monocyte-derived dendritic cells from colorectal cancer patients, non-small-cell-lung-cancer patients and healthy donors |
| Q42279459 | Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN® (dendritic cell-based vaccine): a case report. |
| Q34438014 | Concurrent interaction of DCs with CD4(+) and CD8(+) T cells improves secondary CTL expansion: It takes three to tango. |
| Q35126981 | Current status of dendritic cell immunotherapy of malignancies |
| Q56966277 | Cytokine production and T-cell activation by macrophage-dendritic cells generated for therapeutic use |
| Q35119879 | Dendritic Cell Function in Vivo during the Steady State: A Role in Peripheral Tolerance |
| Q48293590 | Dendritic Cell-Based Cancer Vaccines |
| Q58409682 | Dendritic Cell-Based Immunotherapy |
| Q78840786 | Dendritic cell KLH loading requirements for efficient CD4+ T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines |
| Q35027813 | Dendritic cell gene therapy |
| Q35762464 | Dendritic cell immunotherapy: mapping the way. |
| Q37773266 | Dendritic cell preparation for immunotherapeutic interventions. |
| Q36899104 | Dendritic cell vaccination |
| Q37771941 | Dendritic cell vaccines for the immunocompromised patient: prevention of influenza virus infection |
| Q47343926 | Dendritic cell vaccines--hopeful or hopeless? |
| Q35775188 | Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives |
| Q89347786 | Dendritic cell-based immunotherapy |
| Q37448957 | Dendritic cell-based therapeutic cancer vaccines: what we have and what we need |
| Q37560918 | Dendritic cell-based vaccines in treating recurrent herpes labialis: Results of pilot clinical study |
| Q35116896 | Dendritic cell-mediated immunization in macroglobulinemia |
| Q61050446 | Dendritic cells and follicular dendritic cells express a novel ligand for CD38 which influences their maturation and antibody responses |
| Q35169134 | Dendritic cells and immunotherapy for cancer |
| Q34216506 | Dendritic cells and immunotherapy for malignant disease |
| Q36569018 | Dendritic cells and tumor microenvironment: a dangerous liaison |
| Q36899314 | Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products |
| Q40800781 | Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function |
| Q39946625 | Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis |
| Q34649397 | Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. |
| Q41520681 | Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? |
| Q37513871 | Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4 |
| Q30080006 | Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo |
| Q42982625 | Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8+ T cells and antiviral immunity |
| Q40699456 | Dendritic cells: On the move from bench to bedside |
| Q35618115 | Dendritic cells: a journey from laboratory to clinic |
| Q37176078 | Dendritic cells: at the clinical crossroads |
| Q36986703 | Dendritic cells: understanding immunogenicity |
| Q36939901 | Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting |
| Q40680313 | Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells |
| Q34550189 | Development and use of multimeric major histocompatibility complex molecules |
| Q35622028 | Development of new strategies to prevent type 1 diabetes: the role of animal models. |
| Q43596580 | Direct intralymphatic injection of peptide vaccines enhances immunogenicity. |
| Q35616090 | Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers |
| Q33839267 | Downregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFNγ signaling |
| Q41513634 | Effect of a cancer vaccine prepared by fusions of hepatocarcinoma cells with dendritic cells. |
| Q34658123 | Effect of ex vivo culture duration on phenotype and cytokine production by mature dendritic cells derived from peripheral blood monocytes |
| Q79438871 | Effect of immature dendritic cell injection before heterotropic cardiac allograft |
| Q38649472 | Effect of oxygen levels on the physiology of dendritic cells: implications for adoptive cell therapy |
| Q35224721 | Efficiency of dendritic cell vaccination against B16 melanoma depends on the immunization route |
| Q37599553 | Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. |
| Q64378543 | Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor |
| Q36959680 | Exploiting dendritic cells for active immunotherapy of cancer and chronic infections |
| Q34012742 | Expression of ICAM-1, HLA-DR, and CD80 on peripheral circulating CD1 alpha DCs induced in vivo by IFN-alpha in patients with chronic hepatitis B |
| Q24797848 | Gene therapy for carcinoma of the breast: Genetic immunotherapy |
| Q33787144 | HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other |
| Q43438121 | HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. |
| Q37980404 | Harnessing human plasmacytoid dendritic cells as professional APCs. |
| Q36751608 | Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines |
| Q34712641 | How dendritic cells and microbes interact to elicit or subvert protective immune responses |
| Q61812341 | Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy |
| Q35558537 | Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation |
| Q40727651 | Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes |
| Q34255654 | Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection |
| Q41811366 | Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio |
| Q36483341 | Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. |
| Q34034124 | Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection. |
| Q56961920 | Immune control of HIV-1 after early treatment of acute infection |
| Q29619244 | Immunosuppressive networks in the tumour environment and their therapeutic relevance |
| Q43967044 | Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine |
| Q36243536 | Immunotherapy of cancer in 2012. |
| Q53922274 | In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells. |
| Q34347386 | Increased macrophage infection upon subcutaneous inoculation of rhesus macaques with simian immunodeficiency virus-loaded dendritic cells or T cells but not with cell-free virus |
| Q40647086 | Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. |
| Q40811138 | Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. |
| Q36051654 | Inhibition of human dendritic cell activation by hydroethanolic but not lipophilic extracts of turmeric (Curcuma longa) |
| Q41729705 | Interleukin-10 receptor-1 expression in monocyte-derived antigen-presenting cell populations: dendritic cells partially escape from IL-10's inhibitory mechanisms. |
| Q40886985 | Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus |
| Q46662084 | Langerhans cells are more efficiently transduced than dermal dendritic cells by adenovirus vectors expressing either group C or group B fibre protein: implications for mucosal vaccines. |
| Q51803810 | Large-Scale Immunomagnetic Selection of CD14+Monocytes to Generate Dendritic Cells for Cancer Immunotherapy: A Phase I Study |
| Q37176040 | Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes |
| Q33850510 | Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals |
| Q43265267 | Measurement of cytotoxic T lymphocyte activity of human cytomegalovirus seropositive individuals by a highly sensitive coupled luminescent method |
| Q78567097 | Melanoma vaccines |
| Q34133689 | Metabolic activation in drug allergies. |
| Q35148879 | Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. |
| Q36908551 | Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells |
| Q38877110 | Modulation of innate immunity in the tumor microenvironment |
| Q52005768 | Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. |
| Q45204402 | Monitoring of CD4+ and CD8+ T-cell responses after dendritic cell-based immunotherapy using CFSE dye dilution analysis. |
| Q51827105 | Monocyte-derived dendritic cells from patients with severe forms of chromoblastomycosis induce CD4+ T cell activation in vitro. |
| Q39183391 | Neoepitopes as cancer immunotherapy targets: key challenges and opportunities. |
| Q93018018 | Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment |
| Q45880037 | Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization |
| Q51120716 | Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma. |
| Q35793849 | Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors |
| Q73147768 | Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant |
| Q37735454 | Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors |
| Q40427880 | Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials |
| Q48356056 | Potential applications for plasmacytoid dendritic cells in cancer immunotherapy. |
| Q53575467 | Potential side effects of dendritic cells pulsed with allogenic melanoma cell lysate in mice. |
| Q41855097 | Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy |
| Q64380272 | Presentation of SIVgag to monkey T cells using dendritic cells transfected with a recombinant adenovirus |
| Q27001126 | Primer on tumor immunology and cancer immunotherapy |
| Q34351438 | Processing and presentation of antigens by dendritic cells: implications for vaccines |
| Q33835126 | Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons |
| Q82504063 | Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization |
| Q34712708 | Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection |
| Q36370290 | Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. |
| Q37830226 | Recent developments in cancer vaccines |
| Q28744503 | Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers |
| Q34004618 | Remnants of suicidal cells fostering systemic autoaggression. Apoptosis in the origin and maintenance of autoimmunity |
| Q40632606 | Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells. |
| Q92441659 | Role of Dendritic Cells in Exposing Latent HIV-1 for the Kill |
| Q34801866 | STI and beyond: the prospects of boosting anti-HIV immune responses |
| Q34572198 | Strategies for designing and optimizing new generation vaccines |
| Q64057061 | Strategies for developing and optimizing cancer vaccines |
| Q58409657 | Surrogate markers of response to cancer immunotherapy |
| Q25255724 | Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients |
| Q34541424 | TNF-α and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumors |
| Q36375923 | TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo |
| Q27490919 | Targeted Delivery of Small Interfering RNA to Human Dendritic Cells To Suppress Dengue Virus Infection and Associated Proinflammatory Cytokine Production |
| Q33584637 | Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice |
| Q37175025 | Targeting tumors with LIGHT to generate metastasis-clearing immunity |
| Q34642229 | The Role of Antigen-presenting Cells in HIV Pathogenesis |
| Q26784452 | The Role of Dendritic Cells in Fibrosis Progression in Nonalcoholic Fatty Liver Disease |
| Q33840529 | The control of T cell responses by dendritic cell subsets |
| Q33799165 | The decreased replicative capacity of simian immunodeficiency virus SIVmac239Delta(nef) is manifest in cultures of immature dendritic cellsand T cells |
| Q46062060 | The fabulous legacy of a Nobel Prize Laureate: Ralph M. Steinman, 1943-2011. |
| Q36368355 | The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli |
| Q73143593 | The great escape - AIDS viruses and immune control |
| Q35210456 | The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors |
| Q52964856 | The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2. |
| Q34571978 | The use of dendritic cells in cancer therapy |
| Q52665595 | Tolerogenic Dendritic Cells in Solid Organ Transplantation: Where Do We Stand? |
| Q34632077 | Tracking T cells with tetramers: new tales from new tools |
| Q40560815 | Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. |
| Q35671699 | Tumor vaccines. |
| Q30846001 | Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. |
| Q36265772 | Uric acid enhances the antitumor immunity of dendritic cell-based vaccine |
| Q24801506 | Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial |
| Q36375683 | Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma |
| Q36900143 | Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments |
| Q52344502 | [About Ralph M. Steinman and dendritic cells]. |
Search more.